2014
DOI: 10.1001/jamaophthalmol.2013.5698
|View full text |Cite
|
Sign up to set email alerts
|

Retinal Complications Associated With Pars Plana Vitrectomy for Macular Holes or Epiretinal Membranes in Eyes With Previous Retinal Detachment Repair

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2017
2017
2018
2018

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 4 publications
0
2
0
Order By: Relevance
“…The duration of diabetes directly correlates with the increased risk of the developing this complication, with patients of type 1 diabetes being more susceptible than type 2 diabetic patients . The present clinical treatments of diabetic retinopathy are limited to laser photocoagulation and vitrectomy . Although in the last two decades, researchers have targeted a number of preventive agents such as anti‐vascular endothelial growth factor (VEGF) agents, anti‐TNF‐alpha agents, peroxisome proliferator‐activated receptor (PPAR)‐gamma receptor agonists, all these agents are still on preclinical or clinical testing stages.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The duration of diabetes directly correlates with the increased risk of the developing this complication, with patients of type 1 diabetes being more susceptible than type 2 diabetic patients . The present clinical treatments of diabetic retinopathy are limited to laser photocoagulation and vitrectomy . Although in the last two decades, researchers have targeted a number of preventive agents such as anti‐vascular endothelial growth factor (VEGF) agents, anti‐TNF‐alpha agents, peroxisome proliferator‐activated receptor (PPAR)‐gamma receptor agonists, all these agents are still on preclinical or clinical testing stages.…”
Section: Introductionmentioning
confidence: 99%
“…[1] The present clinical treatments of diabetic retinopathy are limited to laser photocoagulation and vitrectomy. [2,3] Although in the last two decades, researchers have targeted a number of preventive agents such as anti-vascular endothelial growth factor (VEGF) agents, anti-TNF-alpha agents, peroxisome proliferator-activated receptor (PPAR)-gamma receptor agonists, all these agents are still on preclinical or clinical testing stages. One of the successful agents clinically established now are the anti-VEGF agents which primarily act by restricting/inhibiting angiogenesis.…”
Section: Introductionmentioning
confidence: 99%